VitaDAO announced it raised $4.1m in tokens from Pfizer Ventures, Shine Capital, L1 Digital and several other web3 and decentralised science organizations.

VitaDAO has secured $4.1 million in a token-based funding round led by Pfizer Ventures, with participation from Balaji Srinivasan, L1 Digital, and several others. VitaDAO is focused on bringing to life a decentralized longevity therapeutics-focused crowdfunding and research system.

VitaDAO secures $4.1 million in funding
VitaDAO, a longevity therapeutics startup occupying the frontline of decentralized science (DeSci), has raised $4.1 million in a token-based funding round led by Pfizer Ventures, with participation from Shin Capital, L1 Digital, former Coinbase CTO Balaji Srinivasan, and others.

VitaDAO was launched as a DeSci experiment by Molecule, a project aimed at accelerating innovation in the pharmaceuticals sector with innovative technologies like blockchain and NFTs. Molecule raised $12.7 million in its seed funding round last June.

VitaDAO Decentralizing longevity science
With the successful funding, VitaDAO will further develop its DeSci platform, which focuses on funding early-stage longevity research, commercializing longevity therapeutics, and more.

Pfizer Ventures has made it clear that it currently holds VitaDAO’s governance token and it recently participated in the project’s governance proposal

Already, VitaDAO has backed Turn Biotechnologies, a company that develops mRNA medicines for body cell restoration and repairing damages brought about by aging. VitaDAO has also funded a study undertaken by the University of Copenhagen to understand the effects of medicinal drugs on the aging process.

Aside from Pfizer Ventures, Shine Capital and LI Digital also joined the round, alongside fellow decentralized science organizations Beaker DAO and Spaceship DAO; other individual longevity enthusiasts are also pitching in, including Balaji Srinivasan, general partner at a16z and former CTO of Coinbase, and Retro Biosciences CEO Joe Betts-LaCroix.

Learn more…